Commodore Capital LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Commodore Capital LP reported 35 stock positions worth $1.5 billion. Its top holding was Merus (MRUS) at 12.9% of the portfolio, followed by Nuvalent Class A (NUVL, 7.7%) and Xenon Pharmaceuticals (XENE, 7.3%). Compared with Q1 2024, it opened 5 new positions, sold out of 9, added to 15 and reduced 5. The biggest buy was Soleno Therapeutics (SLNO, shares +741%) and the biggest sale an exit from Alpine Immune Sciences (ALPN).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.5B (Q2 2024)
- SEC Filing
- 0001880562-24-000002 ↗ filed Aug 14, 2024
Holdings Value
Holdings 35 stocks · $1.5B
| MRUS Merus NV | 12.92% | 3,200,000 | $189.3M | Reduce -26.6% |
| NUVL Nuvalent Inc. Class A | 7.70% | 1,487,756 | $112.9M | No change |
| XENE Xenon Pharmaceuticals Inc. | 7.33% | 2,754,266 | $107.4M | Add +27.1% |
| PCVX Vaxcyte Inc. | 6.73% | 1,305,000 | $98.5M | Add +51.7% |
| ELVN Enliven Therapeutics Inc. | 6.34% | 3,973,245 | $92.9M | No change |
| VERA Vera Therapeutics Inc. | 6.11% | 2,475,000 | $89.5M | Reduce -21.8% |
| COGT Cogent Biosciences Inc. | 5.60% | 9,738,000 | $82.1M | Add +51.6% |
| SLNO Soleno Therapeutics Inc. | 3.97% | 1,425,000 | $58.1M | Add +740.5% |
| CLDX Celldex Therapeutics Inc. | 3.60% | 1,425,000 | $52.7M | Add +64.5% |
| MIND MEDICINE MINDMED INC | 3.52% | 7,145,888 | $51.5M | Add +22.5% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.43% | 1,225,000 | $50.3M | Add +16.7% |
| ARVN Arvinas Inc. | 3.42% | 1,884,361 | $50.2M | Add +47.8% |
| SYRE Spyre Therapeutics Inc. | 3.19% | 1,988,084 | $46.7M | Add +5.5% |
| CATX Perspective Therapeutics Inc. | 3.17% | 4,657,345 | $46.4M | New |
| PHVS Pharvaris NV | 2.32% | 1,810,175 | $34.0M | Add +4.9% |
| ALKS Alkermes PLC | 2.26% | 1,375,000 | $33.1M | New |
| VRDN Viridian Therapeutics Inc. | 2.25% | 2,528,032 | $32.9M | Add +30.7% |
| KURA Kura Oncology Inc. | 2.24% | 1,593,350 | $32.8M | Add +4.5% |
| NKTX Nkarta Inc. | 1.67% | 4,151,034 | $24.5M | Add +31.1% |
| CELC Celcuity Inc. | 1.64% | 1,464,105 | $24.0M | Reduce -5.9% |
| THRD Third Harmonic Bio Inc. | 1.37% | 1,545,426 | $20.1M | Add +23.6% |
| IMVT Immunovant Inc. | 1.35% | 750,990 | $19.8M | No change |
| ABVX Abivax SA-ADR | 1.16% | 1,284,110 | $17.0M | Reduce -32.2% |
| SNDX Syndax Pharmaceuticals Inc. | 1.16% | 825,000 | $16.9M | Add +158.7% |
| CCCC C4 Therapeutics Inc. | 1.08% | 3,410,384 | $15.8M | No change |
| ORIC Oric Pharmaceuticals Inc. | 0.97% | 2,000,000 | $14.1M | No change |
| APGE Apogee Therapeutics Inc. | 0.78% | 290,000 | $11.4M | No change |
| CABA Cabaletta Bio Inc. | 0.56% | 1,100,000 | $8.2M | No change |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.52% | 750,000 | $7.5M | New |
| NGNE Neurogene Inc. | 0.50% | 200,000 | $7.3M | No change |
| VTGN Vistagen Therapeutics Inc. | 0.37% | 1,575,000 | $5.5M | No change |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.35% | 500,000 | $5.1M | No change |
| AUTL Autolus Therapeutics PLC | 0.28% | 1,178,723 | $4.1M | Reduce -48.8% |
| ARCA BIOPHARMA INC | 0.11% | 414,325 | $1.6M | New |
| AVTX Avalo Therapeutics Inc. | 0.03% | 40,000 | $499K | New |
Portfolio Sells Q1 2024 → Q2 2024
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −3.64 |
| VERA Vera Therapeutics Inc. | Reduce -21.8% | 6.11% | −3.01 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −1.68 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −1.52 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −1.42 |
| AUTL Autolus Therapeutics PLC | Reduce -48.8% | 0.28% | −0.70 |
| ABVX Abivax SA-ADR | Reduce -32.2% | 1.16% | −0.65 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.62 |
| CELC Celcuity Inc. | Reduce -5.9% | 1.64% | −0.61 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −0.29 |
| ACET Adicet Bio Inc. | Sold out | 0.00% | −0.22 |
| MRUS Merus NV | Reduce -26.6% | 12.92% | −0.20 |
| SABS Sab Biotherapeutics Inc. | Sold out | 0.00% | −0.06 |
| DBV TECHNOLOGIES S A | Sold out | 0.00% | −0.00 |
Portfolio Buys Q1 2024 → Q2 2024
| SLNO Soleno Therapeutics Inc. | Add +740.5% | 3.97% | +3.48 |
| CATX Perspective Therapeutics Inc. | New | 3.17% | +3.17 |
| PCVX Vaxcyte Inc. | Add +51.7% | 6.73% | +2.80 |
| COGT Cogent Biosciences Inc. | Add +51.6% | 5.60% | +2.72 |
| ALKS Alkermes PLC | New | 2.26% | +2.26 |
| CLDX Celldex Therapeutics Inc. | Add +64.5% | 3.60% | +1.17 |
| XENE Xenon Pharmaceuticals Inc. | Add +27.1% | 7.33% | +1.09 |
| SNDX Syndax Pharmaceuticals Inc. | Add +158.7% | 1.16% | +0.65 |
| THRD Third Harmonic Bio Inc. | Add +23.6% | 1.37% | +0.58 |
| FRNM Freenome Inc. | New | 0.52% | +0.52 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +16.7% | 3.43% | +0.39 |
| ARCA BIOPHARMA INC | New | 0.11% | +0.11 |
| KURA Kura Oncology Inc. | Add +4.5% | 2.24% | +0.06 |
| AVTX Avalo Therapeutics Inc. | New | 0.03% | +0.03 |
| VRDN Viridian Therapeutics Inc. | Add +30.7% | 2.25% | −0.02 |
| ARVN Arvinas Inc. | Add +47.8% | 3.42% | −0.10 |
| MIND MEDICINE MINDMED INC | Add +22.5% | 3.52% | −0.15 |
| PHVS Pharvaris NV | Add +4.9% | 2.32% | −0.34 |
| NKTX Nkarta Inc. | Add +31.1% | 1.67% | −0.61 |
| SYRE Spyre Therapeutics Inc. | Add +5.5% | 3.19% | −1.59 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |